Last reviewed · How we verify
NCT03829085: PADI
Study of the Diet in Patients With the Diagnostic of Acute Pancreatitis
NA trial testing EARLY ORAL REFEEDING in Pancreatitis, Acute in 120 participants. Completed in 31 December 2018.
31 December 2018
Quick facts
| Lead sponsor | Consorci Sanitari del Garraf |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 120 |
| Start date | 1 June 2017 |
| Primary completion | 31 December 2018 |
| Estimated completion | 31 December 2018 |
| Sites | 1 location across Spain |
Drugs / interventions tested
- EARLY ORAL REFEEDING
Conditions studied
- Pancreatitis, Acute — all drugs for Pancreatitis, Acute →
Sponsor
Consorci Sanitari del Garraf
Who can join
Adults 18 to 95, any sex, with Pancreatitis, Acute. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Acute pancreatitis (AP) is a common condition in emergency services worldwide. Approximately 85% of AP are mild and the patients usually recover within 1 to 2 weeks, not requeiring any critical care and organ support. The management of mild AP conventionally involves fasting, intravenous hydration and adequate analgesia until pain improves in order to prevent stimulation and allow the pancreas gland to rest. The current guidelines recommend the oral food intake should be tried as soon as possible, and beneficial effects or early enteral nutrition with mild AP have been reported in literature. Then, early oral refeeding (EORF) after mild and moderate AP is beneficial, but the optimal timing and starting criteria are unclear. Even now, refeeding after mild and moderate AP is typically started until clinical symptoms have resolved and pancreatic enzymes are decreasing, in a successively increasing manner. The aim of this study is to evaluate length of hospital stay, clinical findings and complications for EORF with immediately full caloric intake in patients with mild and moderate AP.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Immediate Oral Refeeding in Patients With Mild and Moderate Acute Pancreatitis: A Multicenter, Randomized Controlled Trial (PADI trial).
Ramírez-Maldonado E, López Gordo S, Pueyo EM, Sánchez-García A, et al · · 2021 · cited 37× · PMID 33196485 · DOI 10.1097/sla.0000000000004596 -
Response to Comment by Dr. Kuang on Our Manuscript "Immediate Oral Refeeding in Patients With Mild and Moderate Acute Pancreatitis: A Multicenter, Randomized Controlled Trial (PADI trial)".
Ramírez-Maldonado E, López Gordo S, Memba R, Jorba R. · · 2024 · PMID 39310339 · DOI 10.1097/as9.0000000000000472
Verify or expand the search:
- PubMed search for NCT03829085
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Pancreatitis, Acute
Currently open trials in the same condition.
- NCT07267169 — Efferon LPS Hemoadsorption in Patients With Acute Pancreatitis · NA · recruiting
- NCT07244432 — Post-ERCP Pancreatitis - Prophylactic Measures Implementation Study (PEP-PROMIS) · recruiting
- NCT07171112 — Smoking Cessation Trial in Recurrent Acute Pancreatitis and Chronic Pancreatitis · Phase 2 · recruiting
- NCT07202559 — Indometacin With or Without Aggressive Intravenous Hydration to Prevent Pancreatitis After Pancreatic Extracorporeal Sho · NA · recruiting
- NCT07168863 — EUS-guided FNB-induced PANCREatitis Assessment · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03829085 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Consorci Sanitari del Garraf
- Last refreshed: 5 February 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03829085.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing